Osteoarthritis Therapeutics Market Forecasts to 2030 – Global Analysis By Treatment (Viscosupplementation Agents, Corticosteroids, Hyaluronic Acid Injection, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Analgesics and Other Treatments), Anatomy, Route

Osteoarthritis Therapeutics Market Forecasts to 2030 – Global Analysis By Treatment (Viscosupplementation Agents, Corticosteroids, Hyaluronic Acid Injection, Non-steroidal Anti-inflammatory Drugs (NSAIDs), Analgesics and Other Treatments), Anatomy, Route of Administration, Distribution Channel and By Geography

According to Stratistics MRC, the Global Osteoarthritis Therapeutics Market is accounted for $9.6 billion in 2023 and is expected to reach $18.4 billion by 2030 growing at a CAGR of 9.7% during the forecast period. Osteoarthritis therapeutics aim to manage pain, improve joint function, and slow disease progression. Non-pharmacological interventions include exercise, weight management, and physical therapy. Pharmacological options encompass analgesics like acetaminophen and NSAIDs for pain relief, while intra-articular injections of corticosteroids or hyaluronic acid may alleviate symptoms. Disease-modifying drugs such as glucosamine and chondroitin sulfate are also utilized, albeit their efficacy is debated. Surgical interventions like joint replacement surgery are considered in severe cases.

According to a study published by The Lancet in September 2023, globally, 595 million people had osteoarthritis in 2020, with the Asia Pacific region accounting for a prevalence of 8632.7 per 100,000. Such high figures indicate an increasing demand for therapeutics in the region.

Market Dynamics:

Driver:

Growing demand for pain management

As more people seek solutions for osteoarthritis pain, the overall demand for osteoarthritis therapeutics rises. This translates to a larger market with more patients requiring treatment, leading to increased revenue for pharmaceutical companies and healthcare providers offering these therapies and development and marketing of pain-relieving medications specifically designed for osteoarthritis. This includes oral medications like NSAIDs and analgesics, topical applications like creams and gels, and injectable options like corticosteroids and hyaluronic acid enhancing the pain management and further boosting the market growth.

Restraint:

Adverse side effects of medications

Osteoarthritis medications come with unpleasant or even serious side effects, patients might be less likely to take them as prescribed. This can lead to uncontrolled pain, inflammation, and potentially a worsening of the condition and can lead to additional healthcare costs. Patients might experience complications requiring further treatment, such as stomach ulcers from NSAIDs. This puts a strain on healthcare systems and individual budgets. Thus inconsistency in medication use also reduces the effectiveness of the treatment, hindering the overall market performance.

Opportunity:

Rising prevalence of osteoarthritis

As more and more people are diagnosed with osteoarthritis, the demand for treatments naturally increases and focuses on treatments that can help manage osteoarthritis in its early stages, potentially delaying or preventing the need for stronger medications or joint replacements later. This translates to a larger market for pharmaceutical companies and healthcare providers offering osteoarthritis therapeutics.

Threat:

Limited disease modification

The inability to modify the disease course often leads to repeat customers. Patients may require ongoing treatment regimens with the same or progressively stronger medications as their osteoarthritis worsens and can also lead to patient dissatisfaction with available treatments. Patients might feel their condition is not being effectively addressed, as they experience ongoing pain and joint deterioration despite medication use. This creates a cycle of recurring costs for patients and healthcare systems hampering the market growth.

Covid-19 Impact

Telemedicine and remote monitoring gained prominence, influencing prescribing patterns. While demand for symptomatic relief persisted, economic uncertainties may have affected affordability and access to treatments. Research and development efforts faced challenges, but also opportunities for innovation, particularly in remote patient management and virtual clinical trials. Overall, COVID-19 underscored the importance of adaptability, patient-centric approaches, and resilience in navigating market dynamics for osteoarthritis therapeutics.

The viscosupplementation agents segment is expected to be the largest during the forecast period

The viscosupplementation agents segment is estimated to have a lucrative growth, as these agents provide an alternative treatment option for OA patients, especially those who do not respond well to other conventional therapies like NSAIDs or corticosteroid injections. These agents have diversified the treatment options available for osteoarthritis patients. This has led to a more personalized approach to managing the condition, as physicians can now tailor treatment plans based on individual patient needs and preferences.

The knee osteoarthritis segment is expected to have the highest CAGR during the forecast period

The knee osteoarthritis segment is anticipated to witness the highest CAGR growth during the forecast period, because knee osteoarthritis is one of the most common forms of OA, leading to a substantial demand for therapeutics targeting pain relief, inflammation reduction, and improvement in joint function. This high demand drives research and development efforts by pharmaceutical companies to innovate and improve existing treatments or develop new ones specifically tailored for knee osteoarthritis.

Region with largest share:

Asia Pacific is projected to hold the largest market share during the forecast period owing to the increased healthcare spending, population growth, medical advancements, regulatory support, and improved awareness. It's projected to experience significant growth, driven by aging populations and treatment innovation in countries such as China, Japan, and India. Pharmaceutical firms are investing in research collaborations for product development, and a favorable regulatory scenario, driving demand for both symptomatic relief and disease-modifying treatments.

Region with highest CAGR:

North America is projected to have the highest CAGR over the forecast period, due to various factors, including the region's high prevalence of obesity and supportive government policies. Key market players such as Novartis AG, Pfizer, Zimmer Biomet, and GlaxoSmithKline plc further solidify its position. Strategic initiatives such as therapeutics study trials, mergers, acquisitions, and partnerships among pharmaceutical giants are actively shaping the competitive landscape. For instance, in February 2024, Novartis announced further continuation of its study for biological interventions U.S., which are safety, tolerability and efficacy of intra-articular Canakinumab and LNA043 for patients with knee osteoarthritis

Key players in the market

Some of the key players in the Osteoarthritis Therapeutics Market include GlaxoSmithKline plc, Sanofi SA, Bayer AG, Pfizer Inc, Novartis AG, Zimmer Biomet, Assertio Therapeutics, INC., Anika Therapeutics, Bioventus, Ferring Pharmaceuticals Inc., Abbvie Inc., Amgen Inc., Boehringer Ingelheim International GmbH., Samsung Bioepis., Sun Pharmaceutical Industries Ltd., Teva Pharmaceuticals Industries Ltd., AstraZeneca PLC, Stryker Corporation and Merck & Co Inc.

Key Developments:

In April 2024, Novartis implements manufacturing adjustments for ribociclib to ensure alignment with latest regulatory standards in eBC by end of Q2. This does not impact patient use or commercial supply of Kisqali® in its approved indication of metastatic breast cancer (mBC).

In March 2024, ViiV Healthcare announces interim data at CROI indicating superior efficacy of long-acting injectable HIV treatment Cabenuva (cabotegravir + rilpivirine) compared to daily oral therapy in individuals living with HIV who have adherence challenges.

In February 2024, GSK plc announced that it has completed the acquisition of Aiolos Bio (Aiolos), a clinical-stage biopharmaceutical company focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions.

Treatments Covered:
• Viscosupplementation Agents
• Corticosteroids
• Hyaluronic Acid Injection
• Non-steroidal Anti-inflammatory Drugs (NSAIDs)
• Analgesics
• Other Treatments

Anatomies Covered:
• Hip Osteoarthritis
• Hand Osteoarthritis
• Small-Joint Osteoarthritis
• Knee Osteoarthritis
• Ankle Osteoarthritis
• Other Anatomies

Route of Administrations Covered:
• Parenteral Route
• Topical Route
• Oral Route
• Other Route of Administrations

Distribution Channels Covered:
• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• E-Commerce

Regions Covered:
• North America
US
Canada
Mexico
• Europe
Germany
UK
Italy
France
Spain
Rest of Europe
• Asia Pacific
Japan
China
India
Australia
New Zealand
South Korea
Rest of Asia Pacific
• South America
Argentina
Brazil
Chile
Rest of South America
• Middle East & Africa
Saudi Arabia
UAE
Qatar
South Africa
Rest of Middle East & Africa

What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements